SynthesisFrontiers in medicine2026
Effects of liraglutide on blood pressure and renal function in patients with type 2 diabetic nephropathy: a meta-analysis of randomized controlled trials.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The effects of liraglutide on blood pressure in patients with T2DN remain unclear. This meta-analysis aimed to systematically evaluate the effects of liraglutide on blood pressure and renal function in patients with T2DN. Methods: We conducted comprehensive searches of Web of Science, PubMed, the Cochrane Library, Elsevier ScienceDirect, CNKI, Wanfang Data, and VIP databases. Eligible studies were RCTs of ≥12 weeks' duration evaluating liraglutide for T2DN. Two independent reviewers screened citations, extracted data, and assessed methodological quality using the Cochrane Risk-of-Bias Tool. Statistical analyses were performed in Stata 17.0 and RevMan 5.4, with effect sizes presented as RR or MD and 95% CI. The Cochrane Q test and I Results: This meta-analysis included 23 RCTs involving 1,723 participants. Compared with the control group, liraglutide significantly reduced SBP [MD = -5.00, 95% CI (-7.17, -2.84)], while no significant effect was observed on DBP. In addition, liraglutide was associated with favorable changes in some renal biomarkers, as evidenced by reductions in Scr, UACR, Cys-C, BUN, and Conclusion: Liraglutide may be associated with favorable changes in selected BP, renal, metabolic, and inflammatory outcomes in patients with T2DN. However, further high-quality studies are needed to confirm these findings. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251232844, PROSPERO CRD420251232844.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.